Stakeholders will gather to discuss the future of patient-centered health technology assessment at an event hosted by the Innovation and Value Initiative. Jon Campbell, NPC's Chief Science Officer, will join a panel to discuss different approaches to assessing value.
Thursday, March 14, 2024 | 9:30 AM - 3:00 PM
Session:
Is Real Option Value Really an Option for Today’s HTA?
Speakers:
- Jonathan Campbell, MS, PhD, Chief Science Officer, NPC
- Zubair Ansari, Executive Director of Cancer Support Community
- Meng Li, PhD, Assistant Professor at CEVR, Tufts Medical Center
Session Description:
Real Option Value is an approach in value assessment that calculates the benefit patients and caregivers receive from treatments that extend life, giving patients the chance to benefit from future treatment advances. The panel will discuss whether this new method is ready to be put into practice and what would it mean for people with life-threatening conditions.